David V. Batchelor

SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.

D. Walker, M. Trevethick, E. Stuart, 2009, Bioorganic & medicinal chemistry letters.

Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.

Peter G. Dodd, D. Walker, M. Trevethick, 2008, Bioorganic & medicinal chemistry letters.

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.

J. Blagg, A. Baxter, H. Verrier, 2007, Bioorganic & medicinal chemistry letters.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

P. A. Bradley, Brian E Marron, Ian K Gurrell, 2017, Journal of medicinal chemistry.

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.

David W. Gordon, M. Andrews, A. Brown, 2009, Bioorganic & medicinal chemistry letters.

An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).

A. Wood, P. Dorr, D. Pryde, 2011, Journal of medicinal chemistry.